Quick Answer
DiaMedica Therapeutics Inc. reported Net Income Loss of -$32.77 million for the year ending 2025.
- DiaMedica Therapeutics Inc. showed a decrease of -34.0% in Net Income Loss from 2024 to 2025.
- This data is from DiaMedica Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$650.0 thousand | Q2 2018: -$1.74 million | Q3 2018: -$1.39 million | Q1 2019: -$3.25 million | Q2 2019: -$2.47 million | Q3 2019: -$2.45 million | Q1 2020: -$2.43 million | Q2 2020: -$2.47 million | Q3 2020: -$3.19 million | Q1 2021: -$3.62 million | Q2 2021: -$3.27 million | Q3 2021: -$3.45 million | Q1 2022: -$3.51 million | Q2 2022: -$3.36 million | Q3 2022: -$3.06 million | Q1 2023: -$5.27 million | Q2 2023: -$4.48 million | Q3 2023: -$4.47 million | Q1 2024: -$5.15 million | Q2 2024: -$5.12 million | Q3 2024: -$6.27 million | Q1 2025: -$7.71 million | Q2 2025: -$7.70 million | Q3 2025: -$8.62 million.
- Over the full 9 years of available data (2017 to 2025), DiaMedica Therapeutics Inc.'s Net Income Loss has declined by 669.2%.
- Historical annual values: Fiscal year 2025: -$32.77 million | Fiscal year 2024: -$24.44 million | Fiscal year 2023: -$19.38 million | Fiscal year 2022: -$13.68 million | Fiscal year 2021: -$13.59 million | Fiscal year 2020: -$12.29 million | Fiscal year 2019: -$10.65 million | Fiscal year 2018: -$5.73 million | Fiscal year 2017: -$4.26 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: